Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab

The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Transplantation

Sex eligibility

All sexes

Study type

Observational

Primary location

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

all patients considered for transplantation

Exclusion criteria

none

Treatment and study plan

Primary outcomes

The primary outcome is to look for expansion of regulatory T cells at one year.

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

Genzyme, a Sanofi Company

Registry information

Important dates

Study start: 2008
Primary completion: 2010
Study completion: 2011
First posted: Feb 12, 2009
Registry last updated: Jun 29, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed